Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are common in women of childbearing age and are often treated with teratogenic medications. In this study, we assessed contraceptive methods in young women with RA or PsA and correlated contraceptive method efficacy with use of concomitant rheumatic medications. We combined the data from several cross-sectional surveys of women under the age of 40 with RA or PsA. Two surveys recruited participants from a clinic setting (RA and PsA Clinic Surveys), and the third survey recruited participants from CreakyJoints.org, an online forum for patients with inflammatory arthritis (CreakyJoints Survey). Of the 164 women included, 138 had RA (67 in RA Clinic Survey, 71 in CreakyJoints Survey) and 26 had PsA (19 in PsA Clinic Survey, 7 in CreakyJoints Survey). Use of specific contraceptive and rheumatic medications were similar between the clinic and online surveys. In the pooled analysis of the Clinic and CreakyJoints survey data, women with RA and PsA reported similar utilization of highly effective contraception methods (31.9% RA, 34.6% PsA) and effective methods (31.2% RA, 30.8% PsA), but different utilization of ineffective methods (35.5% RA, 11.5% PsA) and no methods (1.5% RA, 23.1% PsA), p = 0.0002. These proportions remained similar across subgroups taking methotrexate, anti-TNF biologics, and novel medications. Approximately two thirds of women with RA and PsA reported using effective or highly effective methods of contraception, though women with PsA were more likely to report no methods of contraception.
KeywordsContraception Fertility Psoriatic arthritis Rheumatoid arthritis
This work was partially supported through a Patient-Centered Outcomes Research Institute (PCORI) award (PPRN-1306-04811).
Compliance with ethical standards
Conflict of interest
The authors JRC, SG, and WBN receive support from a Patient-Centered Outcomes Research Institute (PCORI) award and ArthritisPower is in part supported by this grant. The authors have no other disclosures to report. We have full control of all primary data and agree to allow the journal to review the data if requested.
All statements in this manuscript, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its Board of Governors or Methodology Committee.
- 1.Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Network of French Pharmacovigilance C, Shechtman S, Johnson D, Cuppers-Maarschalkerweerd B, Pistelli A, Clementi M, Winterfeld U, Eleftheriou G, Pupco A, Kao K, Malm H, Elefant E, Koren G, Vial T, Ornoy A, Meister R, Schaefer C (2014) Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol 66(5):1101–1110. https://doi.org/10.1002/art.38368 CrossRefGoogle Scholar
- 2.Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, Doria A, Fischer-Betz R, Forger F, Moraes-Fontes MF, Khamashta M, King J, Lojacono A, Marchiori F, Meroni PL, Mosca M, Motta M, Ostensen M, Pamfil C, Raio L, Schneider M, Svenungsson E, Tektonidou M, Yavuz S, Boumpas D, Tincani A (2017) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76(3):476–485. https://doi.org/10.1136/annrheumdis-2016-209770 CrossRefGoogle Scholar
- 5.Ostensen M, Andreoli L, Brucato A, Cetin I, Chambers C, Clowse ME, Costedoat-Chalumeau N, Cutolo M, Dolhain R, Fenstad MH, Forger F, Wahren-Herlenius M, Ruiz-Irastorza G, Koksvik H, Nelson-Piercy C, Shoenfeld Y, Tincani A, Villiger PM, Wallenius M, von Wolff M (2015) State of the art: reproduction and pregnancy in rheumatic diseases. Autoimmun Rev 14(5):376–386. https://doi.org/10.1016/j.autrev.2014.12.011 CrossRefGoogle Scholar
- 6.Ostensen M, von Esebeck M, Villiger PM (2007) Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol 34(6):1266–1269Google Scholar
- 7.O'Niell C, Ngian GS, Nicholson P, Van Doornum S (2015) Contraceptive use in women with rheumatologic disease taking disease modifying anti-rheumatic drugs. Intern Med J 45(Suppl. 2):44Google Scholar
- 8.Dalkilic E, Tufan AN, Oksuz MF, Sahbazlar M, Coskun BN, Seniz N, Pehlivan Y, Inanc M (2014) Comparing female-based contraceptive methods in patients with systemic lupus erythematosus, rheumatoid arthritis and a healthy population. Int J Rheum Dis 17(6):653–657. https://doi.org/10.1111/1756-185X.12338 CrossRefGoogle Scholar
- 9.Sadun RE, Wells MA, Balevic SJ, Lackey V, Aldridge EJ, Holdgagte N, Mohammad S, Criscione-Schreiber LG, Clowse MEB, Yanamadala M (2018) Increasing contraception use among women receiving teratogenic medications in a rheumatology clinic. BMJ Open Quality 7(3):e000269. https://doi.org/10.1136/bmjoq-2017-000269 CrossRefGoogle Scholar
- 10.Birru Talabi M, Clowse MEB, Blalock SJ, Moreland L, Siripong N, Borrero S (2018) Contraception use among reproductive-age women with rheumatic diseases. Arthritis Care Res. https://doi.org/10.1002/acr.23724
- 11.Pincus T, Swearingen CJ, Bergman M, Yazici Y (2008) RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol 35(11):2136–2147CrossRefGoogle Scholar
- 12.Pincus T, Askanase AD, Swearingen CJ (2009) A multi-dimensional health assessment questionnaire (MDHAQ) and routine assessment of patient index data (RAPID3) scores are informative in patients with all rheumatic diseases. Rheum Dis Clin N Am 35(4):819–827, x. https://doi.org/10.1016/j.rdc.2009.10.017 CrossRefGoogle Scholar